Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp demonstrates a positive financial outlook, evidenced by an anticipated FY25 operating margin of approximately 24%, reflecting an improvement from prior levels. The company's gross margin experienced a notable increase of 240 basis points year-over-year, accompanied by a 390 basis point rise in its operating margin, both surpassing consensus expectations. Growth in the plasma segment was fueled by premium pricing from technology advancements and increased collections, while robust performance in the hospital segment, particularly in the vascular closure business, indicates strong operational momentum and potential for continued revenue expansion.

Haemonetics Corp is facing a challenging financial landscape characterized by declining sales across its key segments, notably a 9.1% organic decline in Plasma sales and a 2.8% decrease in Blood Center sales, which are further compounded by the revision of organic growth expectations downward for both the Hospital and Blood Center segments. The company's overall organic revenue growth has notably slowed to -0.3% in F3Q25, a significant decline from the previous quarter's 3.7% growth, indicating weakening demand and competitive pressures. Furthermore, the updated guidance for FY25 suggests reduced top-line expectations and a narrowing of the non-GAAP EPS range, which raises concerns regarding operating margins and overall earnings performance.